ABSTRACT. Several previous studies indicated that genetic polymorphisms in inflammatory factor genes were associated with glioma risk. However, the relationship between the prostaglandinendoperoxide synthase 2 (PTGS2) genetic polymorphism and glioma remains unclear in the Chinese population. We selected 199 histologically confirmed adult glioma patients and 199 cancer-free controls for the present study and analyzed the distribution of the PTGS2 genotypes and haplotypes. We found that the CC+CT genotype of rs5275 was common in the control group but not in the glioma group (P = 0.033). In addition, we found that the frequency of the C allele was higher in the control group than in the glioma group (P = 0.014). For rs6681231, although we found no significant difference between the 2 groups in genotype distribution, we found that the frequency of the C allele was lower in glioma patients than in control subjects (P = 0.044). We found no significant difference between these 2 groups in the rs689466 genotype and allele distributions. Haplotype analysis suggested that the frequency of the C-A-C haplotype was significantly lower in glioma patients than in control subjects [P = 0.028, odds ratio PTGS2 and glioma (OR) = 0.628, 95% confidence interval (CI) = 0.413-0.955]. However, the frequency of the T-A-G haplotype was higher in glioma patients than in control subjects (P = 0.036, OR = 1.418, 95%CI = 1.022-1.967). Therefore, polymorphisms in the PTGS2 gene may be associated with glioma susceptibility in the Chinese population.
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INTRODUCTION
Glioma, the most common type of brain tumor worldwide, has an incidence rate of approximately 6 in 100,000 people annually. Previous studies have suggested that the 5-year survival rate of glioma patients is approximately 20% (Amirian et al., 2010; Okada et al., 2013) . Therefore, it is very important to identify the factors leading to the development of glioma. Various studies have indicated that risk factors such as exposure to ionizing radiation , genetic polymorphisms (Amirian et al., 2010; Liang et al., 2013; Zeybek et al., 2013; Cheng et al., 2013) , and family history of cancer (Goodenberger and Jenkins, 2012) are associated with glioma.
Previous studies have also indicated that allergic or inflammatory reactions were inversely associated with glioma risk (Turner et al., 2013; Schebesch et al., 2013) . In the brain, the anti-inflammatory properties of interleukin-4 and interleukin-13 are likely based on their abilities to enhance cyclooxygenase (COX)-2 expression, causing cell death of activated microglia (Chen et al., 2012) . Several studies have demonstrated that COX-2 expression is associated with glioma angiogenesis (Jankovsky et al., 2013; Erdem et al., 2013) . Sivak-Sears et al. (2004) reported an inverse association between nonsteroidal anti-inflammatory drug use and glioblastoma risk, which is consistent with the results of other studies. COX-2 is encoded by the prostaglandin-endoperoxide synthase 2 (PTGS2) gene. Single nucleotide polymorphisms (SNPs) in PTGS2 have been reported to be associated with the risk of various cancers, such as prostate cancer (Jhang et al., 2013) , breast cancer (Thorat et al., 2013) , and bladder cancer (Bhattacharya et al., 2013) . However, the role of such SNPs in the PTGS2 gene on the risk of glioma remains unclear.
We performed a case-control study to determine the relationship between PTGS2 genetic polymorphisms and the risk of glioma in a Chinese population.
MATERIAL AND METHODS

Subjects
This study was approved by the Ethics Committee of the First People's Hospital of Shenyang. All participants signed inform consent forms before participating in the study. Glioma patients and control subjects were enrolled in the First People's Hospital of Shenyang between July 2001 and July 2013. For the glioma patients, we initially identified 212 subjects diagnosed with glioma (International Classification of Disease, Oncology, Third Edition [ICD-O-3] morphology codes 9380-9411, 9420-9480, and 9505). We subsequently excluded 13 case subjects diagnosed with medulloblastoma or primitive neuroectodermal tumor (ICD-O-3 codes 9470-9474). A total of 199 glioma patients were included in the present study, of which 123 were males and 76 were females, aged 25-74 years (mean, 63 ± 11.3 years). A total of 199 control subjects were matched to case subjects within a 2-year age interval and for gender. Control subjects were also required to be alive and free from any cancer.
Genotyping
We performed a haplotype-based case-control study; therefore, we genotyped the tagSNPs of PTGS2. We utilized the Haploview 4.2 software based on the HapMap phase II database and obtained 3 tagging SNPs (rs6681231, rs5275, and rs689466) for Han Chinese with minor allele frequency ≥0.15 and r 2 ≥ 0.8 (Figure 1 ). Genomic DNA was extracted from peripheral blood leukocytes using a DNA extraction Kit (Beijing Bioteke Co. Ltd., Beijing, China). Genotyping was confirmed using the TaqMan method as described by Xie et al. (2009 Xie et al. ( , 2011 .
Statistical analyses
The SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA) was utilized to perform data analysis. We utilized the c 2 test to assess Hardy-Weinberg equilibrium and to compare the difference between the case and control groups regarding the allele and genotype distribution. We calculated the odds ratios (ORs) and 95% confidence intervals (95%CIs) using unconditional logistic regression. The SHEsis software was utilized to perform linkage disequilibrium analysis and haplotype analysis. Haplotypes with a frequency of <0.02 were excluded. Statistical significance was established at P < 0.05.
RESULTS
Subjects and general characteristics
A total of 398 subjects were recruited in this case-control study, including 199 glioma patients and 199 cancer-free controls. The clinical characteristics of these 2 groups are shown in Table 1 . There were no significant differences between glioma patients and cancer-free controls in terms of age, gender, alcohol consumption, and smoking (all P > 0.05). 
PTGS2 polymorphisms and glioma
We found that the CC+CT genotype of rs5275 was more common in the control group than in the glioma group (P = 0.033). In addition, the C allele frequency was higher in the control group than in the glioma group (P = 0.014). For rs6681231, although we did not observe a significant difference between the 2 groups in genotype distribution, we found that the C allele frequency was lower in glioma patients than in control subjects (P = 0.044). We found no significant difference between these 2 groups for the rs689466 genotype and allele distributions (Table 2) . As shown in Figure 2 , all 3 SNPs are located in 1 haplotype block (|D'| > 0.5) and were available for haplotype analysis (r 2 < 0.5). As shown in Table 3 , the frequency of the C-A-C haplotype was significantly lower in glioma patients than in control subjects (P = 0.028, OR = 0.628, 95%CI = 0.413-0.955). However, the frequency of the T-A-G haplotype was higher in glioma patients than in control subjects (P = 0.036, OR = 1.418, 95%CI = 1.022-1.967) ( Table 3 ). 
DISCUSSION
In the present study, we found that PTGS2 genetic polymorphisms and haplotypes were associated with glioma. This is the first study to reveal the relationship between PTGS2 genetic polymorphisms and glioma risk in a Chinese population.
COX is a key enzyme involved in the production of prostaglandins from free arachidonic acid; two COX isoforms have been identified (Xie et al., 2011) . These isoforms show differences in expression and function. COX-1 is constitutively expressed in most normal tissues, while COX-2 is rarely expressed in normal tissues. COX-1 is thought to be a housekeeping enzyme that is responsible for various physiological functions. However, COX-2 is rapidly induced in response to cytokines, growth factors, and tumor promoters. COX-2-derived prostaglandins participate in immune response suppression, which has been associated with glioma. COX-2 is encoded by the PTGS2 gene, which is reportedly associated with the risk of various cancers, such as prostate, breast, and bladder cancers.
In the present study, we found that the rs5275 SNP was inversely associated with glioma risk. rs5275 is located in the 3'-untranslated region of the PTGS2 gene and may influence PTGS2 RNA half-life. Previous studies suggested that in the proximal upstream region of rs5275, a conserved AU-rich sequence element is present that mediates posttranscriptional degradation of PTGS2 mRNA. A previous study involving functional analysis to measure PTGS2 mRNA indicated that a decreased cancer risk was associated with the rs5275 C allele. The mechanism of this function may be related to lower PTGS2 expression.
In this study, we found that the C allele of rs5275 was more common in the control group than in the glioma group, indicating that C allele carriers may have decreased risk of glioma. We also found that rs6681231 was associated with glioma. To further understand the role of these SNPs, we constructed 4 haplotypes using these 3 SNPs. We found that the frequency of the C-A-C haplotype was significantly lower in glioma patients than in control subjects. However, the frequency of the T-A-G haplotype was higher in glioma patients than in control subjects.
In conclusion, the present study suggested that genetic polymorphisms in PTGS2 were associated with glioma in a Chinese population. The T-A-G haplotype may be a genetic marker for the risk of glioma, but the C-A-C haplotype may act as a protective factor against glioma.
